PEN Stock Surges 19% With A 6-day Winning Spree On Price Target Hikes
Penumbra (PEN) – a manufacturer of aspiration-based thrombectomy and neurosurgical devices – hit 6-day winning streak, with cumulative gains over this period amounting to a 19%. The company market cap has surged by about $2.2 Bil over the last 6 days, and currently stands at $14 Bil.
The stock has YTD (year-to-date) return of 15.3% compared to 1% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Rally?
[1] Multiple Analyst Price Target Hikes
- RBC Capital Raised Target To $374
- Truist Securities Raised Target To $374
- Impact: Heightened Investor Focus, Increased Trading Volume
Opportunity or Trap?
Below is our take on valuation.
There is not much to fear in PEN stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (For details, see Buy or Sell PEN).
But here is the real interesting point.
You are reading about this 19% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for PEN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PEN | S&P 500 |
|---|---|---|
| 1D | 0.2% | 0.5% |
| 6D (Current Streak) | 19.1% | -0.7% |
| 1M (21D) | 13.5% | 1.2% |
| 3M (63D) | 44.0% | 2.6% |
| YTD 2026 | 15.3% | 1.0% |
| 2025 | 30.9% | 16.4% |
| 2024 | -5.6% | 23.3% |
| 2023 | 13.1% | 24.2% |
However, big gains can follow sharp reversals – but how has PEN behaved after prior drops? See PEN Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 43 S&P constituents with 3 days or more of consecutive gains and 29 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 29 | 16 |
| 4D | 7 | 5 |
| 5D | 2 | 6 |
| 6D | 2 | 2 |
| 7D or more | 3 | 0 |
| Total >=3 D | 43 | 29 |
Key Financials for Penumbra (PEN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.1 Bil | $1.2 Bil |
| Operating Income | $91.8 Mil | $86.2 Mil |
| Net Income | $91.0 Mil | $14.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $339.5 Mil | $354.7 Mil |
| Operating Income | $40.8 Mil | $48.8 Mil |
| Net Income | $45.3 Mil | $45.9 Mil |
While PEN stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.